tetano
Editor, Senior Moderator
BMC Infect Dis. 2020 Mar 20;20(1):240. doi: 10.1186/s12879-020-4948-5.
Influenza in the school-aged population in Mexico: burden of disease and cost-effectiveness of vaccination in children.
Falc?n-Lezama JA[SUP]1[/SUP], Saucedo-Mart?nez R[SUP]1[/SUP], Betancourt-Cravioto M[SUP]1[/SUP], Alfaro-Cortes MM[SUP]1[/SUP], Bahena-Gonz?lez RI[SUP]1[/SUP], Tapia-Conyer R[SUP]2,[/SUP][SUP]3[/SUP].
Author information
Abstract
BACKGROUND:
The current national influenza vaccination schedule in Mexico does not recommend vaccination in the school-aged population (5-11 years). Currently, there are limited data from middle-income countries analysing the cost-effectiveness of influenza vaccination in this population. We explored the clinical effects and economic benefits of expanding the current national influenza vaccination schedule in Mexico to include the school-aged population.
METHODS:
A static 1-year model incorporating herd effect was used to assess the cost-effectiveness of expanding the current national influenza vaccination schedule of Mexico to include the school-aged population. We performed a cross-sectional epidemiological study using influenza records (2009-2018), death records (2010-2015), and discharge and hospitalisation records (2010-2016), from the databases of Mexico's Influenza Surveillance System (SISVEFLU), the National Mortality Epidemiological and Statistical System (SEED), and the Automated Hospital Discharge System (SAEH), respectively. Cost estimates for influenza cases were based on 7 scenarios using data analysed from SISVEFLU; assumptions for clinical management of cases were defined according to Mexico's national clinical guidelines. The primary health outcome for this study was the number of influenza cases avoided. A sensitivity analysis was performed using conservative and optimistic parameters (vaccination coverage: 30% / 70%, Vaccine effectiveness: 19% / 68%).
RESULTS:
It was estimated that expanding the influenza immunisation programme to cover school-aged population in Mexico over the 2018-2019 influenza season would result in 671,461 cases of influenza avoided (50% coverage and 50% effectiveness assumed). Associated with this were 262,800 fewer outpatient consultations; 154,100 fewer emergency room consultations; 97,600 fewer hospitalisations, and 15 fewer deaths. Analysis of cases avoided by age-group showed that 55.4% of them were in the school-aged population, and the decrease in outpatient consultations was largest in this population. There was an overall decrease in the economic burden for the Mexican health care system of 111.9 million US dollars; the immunization programme was determined to be cost-saving in the base, conservative and optimistic scenarios.
CONCLUSIONS:
Vaccinating school-aged population in Mexico would be cost-effective; expansion of the current national vaccination schedule to this age group is supported.
KEYWORDS:
Burden of disease; Cost effectiveness; Influenza; Mexico; Middle-income countries; School-aged population; Vaccination
PMID:32197591PMCID:PMC7085158DOI:10.1186/s12879-020-4948-5
Free PMC Article
Influenza in the school-aged population in Mexico: burden of disease and cost-effectiveness of vaccination in children.
Falc?n-Lezama JA[SUP]1[/SUP], Saucedo-Mart?nez R[SUP]1[/SUP], Betancourt-Cravioto M[SUP]1[/SUP], Alfaro-Cortes MM[SUP]1[/SUP], Bahena-Gonz?lez RI[SUP]1[/SUP], Tapia-Conyer R[SUP]2,[/SUP][SUP]3[/SUP].
Author information
Abstract
BACKGROUND:
The current national influenza vaccination schedule in Mexico does not recommend vaccination in the school-aged population (5-11 years). Currently, there are limited data from middle-income countries analysing the cost-effectiveness of influenza vaccination in this population. We explored the clinical effects and economic benefits of expanding the current national influenza vaccination schedule in Mexico to include the school-aged population.
METHODS:
A static 1-year model incorporating herd effect was used to assess the cost-effectiveness of expanding the current national influenza vaccination schedule of Mexico to include the school-aged population. We performed a cross-sectional epidemiological study using influenza records (2009-2018), death records (2010-2015), and discharge and hospitalisation records (2010-2016), from the databases of Mexico's Influenza Surveillance System (SISVEFLU), the National Mortality Epidemiological and Statistical System (SEED), and the Automated Hospital Discharge System (SAEH), respectively. Cost estimates for influenza cases were based on 7 scenarios using data analysed from SISVEFLU; assumptions for clinical management of cases were defined according to Mexico's national clinical guidelines. The primary health outcome for this study was the number of influenza cases avoided. A sensitivity analysis was performed using conservative and optimistic parameters (vaccination coverage: 30% / 70%, Vaccine effectiveness: 19% / 68%).
RESULTS:
It was estimated that expanding the influenza immunisation programme to cover school-aged population in Mexico over the 2018-2019 influenza season would result in 671,461 cases of influenza avoided (50% coverage and 50% effectiveness assumed). Associated with this were 262,800 fewer outpatient consultations; 154,100 fewer emergency room consultations; 97,600 fewer hospitalisations, and 15 fewer deaths. Analysis of cases avoided by age-group showed that 55.4% of them were in the school-aged population, and the decrease in outpatient consultations was largest in this population. There was an overall decrease in the economic burden for the Mexican health care system of 111.9 million US dollars; the immunization programme was determined to be cost-saving in the base, conservative and optimistic scenarios.
CONCLUSIONS:
Vaccinating school-aged population in Mexico would be cost-effective; expansion of the current national vaccination schedule to this age group is supported.
KEYWORDS:
Burden of disease; Cost effectiveness; Influenza; Mexico; Middle-income countries; School-aged population; Vaccination
PMID:32197591PMCID:PMC7085158DOI:10.1186/s12879-020-4948-5
Free PMC Article